Bronchiectasis is a heterogeneous condition and may be encountered as a stand-alone pulmonary disease by primary care clinicians and specialists in pulmonary medicine. Bronchiectasis sometimes ...

BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing, ...

Please provide your email address to receive an email when new articles are posted on . The population-based cohort study included 3,858,422 participants from the 2009 National Health Screening ...

Bronchiectasis is a condition where the bronchial tubes of your lungs are permanently damaged, widened, and thickened. These damaged air passages allow bacteria and mucus to build up and pool in your ...

Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...

Bronchiectasis is a lung condition that causes a persistent cough and excess phlegm, or sputum. It is a permanent condition that gets worse over time. It can be fatal. The bronchi dilate, usually ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis has demonstrated benefits of an investigational, once-a-day pill called brenso catib as ...

Bronchiectasis is a chronic condition of the respiratory system that is due to abnormal widening of the airways as a consequence of an initial damaging factor. The bronchi, located between the trachea ...

Bronchiectasis is a chronic condition of the respiratory system, in which there is abnormal widening of the airways due to an initial damaging factor. This in turn reduces the ability of the bronchi ...

WEDNESDAY, Aug. 13, 2025 (HealthDay News) — For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has approved Insmed’s daily pill ...